Combination Regimen of Teniposide, PD-1 Monoclonal Antibody and Selinixor for Patients With Relapsed or Refractory PCNSL

This study aims to evaluate the efficacy and safety of the VPX regimen, a novel combination of teniposide, PD-1 monoclonal antibody and selinexor, in patients with relapsed/refractory (R/R) primary central nervous system lymphoma (PCNSL) who have progressed after high-dose methotrexate (HD-MTX)-based systemic therapy. By investigating this therapeutic approach, we seek to establish a new treatment paradigm that may improve clinical outcomes of this high-risk population.

NCT Number	NCT07074470
Lead Sponsor	The First Affiliated Hospital of Soochow University
Conditions	Primary Central Nervous System Lymphoma (PCNSL)
Enrollment	40 participants
Start Date	2025-01-02
Primary Completion	2030-01-02 (estimated)
Study Completion	2032-01-02 (estimated)
Updated on ClinicalTrials.gov	2025-07-20